

**Brilliant Violet 421™ anti-mouse CD21/CD35 (CR2/CR1)**

**Catalog # / Size:** 1217105 / 125 µl  
1217110 / 50 µg

**Clone:** 7E9

**Isotype:** Rat IgG2a, κ


**Immunogen:** CD35/CFA

**Reactivity:** Mouse

**Preparation:** The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 421™ under optimal conditions. The solution is free of unconjugated Brilliant Violet 421™ and unconjugated antibody.

**Formulation:** microL size: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).  
microg size: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).

**Concentration:** microL size: lot-specific



C57BL/6 splenocytes stained with CD21/CD35 (clone 7E9) Brilliant Violet 421™ (filled histogram) or rat IgG2a, κ Brilliant Violet 421™ isotype control (open histogram).

**Applications:**

**Applications:** Flow Cytometry

**Recommended Usage:** Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining using the microL size, the suggested use of this reagent is ≤5 microL per million cells or 5 microL per 100 microL of whole blood. For flow cytometric staining using the microg size, the suggested use of this reagent is ≤0.35 microg per million cells in 100 microL volume. It is recommended that the reagent be titrated for optimal performance for each application.

Brilliant Violet 421™ excites at 405 nm and emits at 421 nm. The standard bandpass filter 450/50 nm is recommended for detection. Brilliant Violet 421™ is a trademark of Sirigen Group Ltd.

This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.

**Application References:** 1. Boackle S, *et al.* 2001 *Immunity* 15:775.

**Description:** CD21, also known as CR2 (complement receptor 2) and C3d receptor, binds C3d and iC3b. It is also a receptor of Epstein-Barr virus. CD35, also known as CR1, binds C3b, iC3b, C4b, and iC4b. CD21/CD35 is primarily expressed on B lymphocytes, mast cells, follicular dendritic cells, macrophages, and activated granulocytes. CD21/CD35 forms part of the B-cell antigen receptor complex with

CD19 and CD81 and is involved in signal transduction.

**Antigen**  
**References:**

1. Kozono Y, *et al.* 1998. *J. Immunol.* 160:1562.
2. Shimizu I, *et al.* 2007. *Blood* 109:1773.
3. Roozendaal R and MC. Carroll. 2007. *Immunol. Rev.* 219:157.